Myelofibrosis Treatment Option | OJJAARA (momelotinib)

You are using an unsupported browser.

Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Sorry, your browser window is too small.

Some features of this site may not function properly. For optimal user experience, please view this site in a larger browser window.

For US Residents

Talk to your doctor to see if OJJAARA is right for you.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Trademarks are owned by or licensed to the GSK group of companies.